Showing results (2391-2400 of 10,003) with videos related to
Sort By:
Pageof 1,001
Leukemia & Lymphoma|February 7, 2024
Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factorsJean A Yared, Tsung-Ying Lee, Catherine E Cooke, et al.Leukemia & Lymphoma|February 20, 2024
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases RegistryDiva Baggio, Cameron Wellard, Eliza Chung, et al.Leukemia & Lymphoma|February 21, 2024
Potential genetic mechanisms driving B/myeloid conversion in patients with follicular lymphoma and Langerhans cell neoplasmsMehrnoosh Tashakori, L Jeffrey MedeirosLeukemia & Lymphoma|February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparisonKatja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.Leukemia & Lymphoma|January 31, 2024
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphomaMatthew M Lei, Mark N Sorial, Uvette Lou, et al.Leukemia & Lymphoma|August 1, 2023
Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a reviewFranco Locatelli, Bijal Shah, Tracy Thomas, et al.Leukemia & Lymphoma|March 24, 2026
When evaluating targeted therapies in chronic lymphocytic leukemia, the absolute measure of treatment effect should be preferredVincent Lévy, Etienne Lengline, Sylvie ChevretLeukemia & Lymphoma|March 30, 2026
A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaJ Croden, G Garcia-Manero, K Chien, et al.Leukemia & Lymphoma|April 12, 2024
Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectivelyFumiyo Maekawa, Masahiko Hayashida, Kayo Takeoka, et al.Leukemia & Lymphoma|April 18, 2024
Management of relapsed/refractory mantle cell lymphomaMusa Alzahrani, Diego VillaPageof 1,001